英文标题：Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: Results of the global, randomized, phase 3 VERITAC-2 study

中文标题：Vepdegestrant[一种PROTAC雌激素受体（ER）降解剂]对比氟维司群用于ER+/人表皮生长因子受体2（HER2）-晚期乳腺癌：全球随机Ⅲ期VERITAC-2研究结果

讲者：Erika P. Hamilton, MD | Breast Cancer Research Program, Sarah Cannon Research Institute

英文标题：Patient-reported outcomes (PROs) in patients with ER+, HER2- advanced breast cancer (ABC) treated with imlunestrant, investigator’s choice standard endocrine therapy, or imlunestrant + abemaciclib: Results from the phase III EMBER-3 trial

中文标题：ER+/HER2-晚期乳腺癌（ABC）患者接受imlunestrant、研究者选择的标准内分泌治疗或imlunestrant联合abemaciclib的患者报告结局（PROs）：Ⅲ期EMBER-3试验结果

讲者：Giuseppe Curigliano, MD, PhD | Istituto Europeo di Oncologia, IRCCS, University of Milano

英文标题：INAVO120: Phase III trial final overall survival (OS) analysis of first-line inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC)

中文标题：Ⅲ期INAVO120试验最终总生存（OS）期分析：inavoisib（INAVO）/安慰剂（PBO） +哌柏西利（PALBO）+氟维司群（FULV）一线治疗PIK3CA突变的内分泌耐药的HR+/HER2-晚期乳腺癌患者

讲者：Nicholas C. Turner, MD, PhD | Royal Marsden Hospital and Institute of Cancer

英文标题：Phase I/Ib study of inavolisib (INAVO) alone and in combination with endocrine therapy ± palbociclib (PALBO) in patients (pts) with PIK3CA-mutated, hormone receptor–positive, HER2-negative locally advanced/metastatic breast cancer (HR+, HER2– LA/mBC): Analysis of hyperglycemia (HG) in prediabetic/obese pts

中文标题：Inavolisib（INAVO）单药及联合内分泌治疗±哌柏西利（PALBO）治疗PIK3CA突变、HR+/HER2–局部晚期/转移性乳腺癌的I/Ib期研究：糖尿病前期/肥胖患者的高血糖（HG）分析

讲者：Mafalda Oliveira, MD, PhD | Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO)

英文标题：A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER2-negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4/6 inhibitor and aromatase inhibitor: The CCTG/BCT MA.40/FINER study (NCT04650581)

中文标题：氟维司群联合ipatasertib对比安慰剂治疗一线CDK4/6抑制剂和芳香酶抑制剂进展后的晚期HER2-/ER+乳腺癌的Ⅲ期双盲随机试验：CCTG/BCT MA.40/FINER研究（NCT04650581）

讲者：Stephen K. L. Chia, MD, FRCPC | BC Cancer Agency

英文标题：Phase III of oral paclitaxel (DHP107) vs intravenous paclitaxel in HER2-negative recurrent or metastatic breast cancer (mBC): Primary analysis of a multinational optimal trial (NCT03315364)

中文标题：口服紫杉醇（DHP107）对比静脉紫杉醇治疗HER2-复发或转移性乳腺癌（mBC）的Ⅲ期研究：跨国优化试验（NCT03315364）的主要分析

讲者：Sung-Bae Kim, MD | Asan Medical Center, University of Ulsan College of Medicine

英文标题：Exploratory biomarker analysis of trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in HER2-low/ultralow, hormone receptor–positive (HR+) metastatic breast cancer (mBC) in DESTINY-Breast06 (DB-06)

中文标题：DESTINY-Breast06（DB-06）研究中，trastuzumab deruxtecan（T-DXd）对比医师选择化疗（TPC）治疗HER2低/超低表达、HR+转移性乳腺癌的探索性生物标志物分析

讲者：Rebecca Alexandra Dent, MD, FASCO | National Cancer Centre Singapore

英文标题：Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1–positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study

中文标题：Sacituzumab govitecan（SG）+帕博利珠单抗（pembro）对比化疗（chemo）+帕博利珠单抗用于初治PD-L1+晚期TNBC：Ⅲ期ASCENT-04/KEYNOTE-D19研究主要结果

讲者：Sara M. Tolaney, MD, MPH, FASCO | Dana-Farber Cancer Institute and Harvard Medical School

英文标题：De-escalated neoadjuvant taxane plus trastuzumab and pertuzumab with or without carboplatin in HER2-positive early breast cancer (neoCARHP): A multicentre, open-label, randomised, phase 3 trial

中文标题：降阶梯紫杉类+曲妥珠单抗和帕妥珠单抗联合或不联合卡铂新辅助治疗HER2+早期乳腺癌（neoCARHP）：一项多中心、开放标签、随机Ⅲ期试验

讲者：王坤，广东省人民医院

英文标题：Predicting pathologic complete response (pCR) from clinicopathologic variables and HER2DX genomic test in stage II/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): Secondary results from the EA1181/CompassHER2 pCR trial

中文标题：基于临床病理变量和HER2DX基因组检测预测Ⅱ/Ⅲ期HER2+乳腺癌接受紫杉类+曲妥珠单抗+帕妥珠单抗（THP）治疗的病理学完全缓解（pCR）率：EA1181/CompassHER2 pCR试验的次要结果

讲者：Nadine M. Tung, MD, FASCO | Beth Israel Deaconess Medical Center

英文标题：Prediction of survival after de-escalated neoadjuvant therapy in HER2+ early breast cancer: A pooled analysis of three WSG trials

中文标题：HER2+早期乳腺癌降阶梯新辅助治疗后生存预测：三项WSG试验的汇总分析

讲者：Monika Karla Graeser, MD | West German Study Group and Ev. Hospital Bethesda, Breast Center Niederrhein, Moenchengladbach, Germany and Department of Gynecology, University Medical Center Hamburg

英文标题：Comparison of marking techniques for target lymph nodes in 2,596 patients with node-positive breast cancer treated with neoadjuvant chemotherapy: Results from the prospective multicenter AXSANA/EUBREAST-03/AGO-B-053 study 

中文标题：2596例淋巴结阳性乳腺癌新辅助化疗患者靶向淋巴结标记技术的比较：前瞻性多中心AXSANA/EUBREAST-03/AGO-B-053研究结果

讲者：Maggie Banys-Paluchowski, PhD | Department of Obstetrics and Gynecology, University Hospital of Schleswig Holstein, Campus Lübeck

英文标题：15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer (BC) in the SOFT and TEXT trials assessing benefits from adjuvant exemestane (E) + ovarian function suppression (OFS) or tamoxifen (T)+OFS

中文标题：SOFT与TEXT试验中绝经前激素受体阳性早期乳腺癌患者的15年结局：辅助依西美坦（E）+卵巢功能抑制（OFS）对比他莫昔芬（T）+OFS的获益评估

讲者：Prudence A. Francis, MD, FRACP | Peter MacCallum Cancer Centre

英文标题：Updated survival outcomes and predictors of benefit from ovarian function suppression in premenopausal women with hormone-receptor–positive breast cancer: Results from the ASTRRA trial

中文标题：更新生存结局及卵巢功能抑制对绝经前激素受体阳性乳腺癌患者的获益预测：ASTRRA试验结果

讲者：Jai Min Ryu, MD, PhD | Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine

英文标题：The impact of ovarian function suppression with adjuvant endocrine therapy on survival outcomes in young germline BRCA mutation carriers with breast cancer: Secondary analysis of an international cohort study

中文标题：辅助内分泌治疗联合卵巢功能抑制对年轻乳腺癌胚系BRCA突变携带者生存结局的影响：一项国际队列研究的二次分析

讲者：Paola Zagami, MD | UNC Lineberger Comprehensive Cancer Center/University of Milan/ European institute of Oncology IRCSS (IEO)